Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes

Open access
Weber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., Berger, J. · 2014 · Human Molecular Genetics

Abstract

X-linked adrenoleukodystrophy (X-ALD) is a fatal neurodegenerative disease caused by mutations in the ABCD1 gene, encoding a member of the peroxisomal ABC transporter family. The ABCD1 protein transports CoA-activated very long-chain fatty acids (VLCFAs) into peroxisomes for degradation via β-oxidation. In the severest form, X-ALD patients suffer from inflammatory demyelination of the brain. As the extent of the metabolic defect in the main immune cells is unknown, we explored their phenotypes concerning mRNA expression pattern of the three peroxisomal ABC transporters, VLCFA accumulation and peroxisomal β-oxidation. In controls, ABCD1 expression was high in monocytes, intermediate in B cells and low in T cells; ABCD2 expression was extremely low in monocytes, intermediate in B cells and highest in T cells; ABCD3 mRNA was equally distributed. In X-ALD patients, the expression patterns remained unaltered; accordingly, monocytes, which lack compensatory VLCFA transport by ABCD2, displayed the severest biochemical phenotype with a 6-fold accumulation of C26:0 and a striking 70% reduction in peroxisomal β-oxidation activity. In contrast, VLCFA metabolism was close to control values in B cells and T cells, supporting the hypothesis that sufficient ABCD2 is present to compensate for ABCD1 deficiency. Thus, the vulnerability of the main immune cell types is highly variable in X-ALD. Based on these results, we propose that in X-ALD the halt of inflammation after allogeneic hematopoietic stem cell transplantation relies particularly on the replacement of the monocyte lineage. Additionally, these findings support the concept that ABCD2 is a target for pharmacological induction as an alternative therapeutic strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddt645

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Peroxisomal ABCD transporters are differentially expressed in the main immune cells. The mRNA levels of ABCD1, ABCD2 and ABCD3 were measured by qRT-PCR in the indicated immune cell types in (A) healthy controls and (B) AMN patients. Absolute copy numbers of mRNA were normalized to the reference gene hypoxanthine phosphoribosyltransferase (HPRT). Values represent means ± SEM. The number of individuals (n) is indicated below the graphs.
Figure 1. Peroxisomal ABCD transporters are differentially expressed in the main immune cells. The mRNA levels of ABCD1, ABCD2 and ABCD3 were measured by qRT-PCR in the indicated immune cell types in (A) healthy controls and (B) AMN patients. Absolute copy numbers of mRNA were normalized to the reference gene hypoxanthine phosphoribosyltransferase (HPRT). Values represent means ± SEM. The number of individuals (n) is indicated below the graphs.CC BY · PubMed Central
Figure 2. There is neither compensatory feedback regulation of ABCD1 nor up-regulation of ABCD2 or ABCD3 mRNAs in immune cells of AMN patients. Statistical analysis of the fold change of ABCD1, ABCD2 and ABCD3 mRNA levels normalized to HPRT for AMN versus healthy control revealed no statistically significant differences. ABCD2 mRNA levels in monocytes and granulocytes were close to the detection limit in both, controls and AMN patients, therefore apparent differences in their expression levels are not considered relevant. F-test showed no significant difference for the population factor (AMN; healthy controls) in all investigated cell types with the exception of NKT cells. However, further analysis of NKT cells with Student's t-test did not confirm a significant difference.
Figure 2. There is neither compensatory feedback regulation of ABCD1 nor up-regulation of ABCD2 or ABCD3 mRNAs in immune cells of AMN patients. Statistical analysis of the fold change of ABCD1, ABCD2 and ABCD3 mRNA levels normalized to HPRT for AMN versus healthy control revealed no statistically significant differences. ABCD2 mRNA levels in monocytes and granulocytes were close to the detection limit in both, controls and AMN patients, therefore apparent differences in their expression levels are not considered relevant. F-test showed no significant difference for the population factor (AMN; healthy controls) in all investigated cell types with the exception of NKT cells. However, further analysis of NKT cells with Student's t-test did not confirm a significant difference.CC BY · PubMed Central
Figure 3. Fatty acid levels in immune cells of healthy controls and AMN patients. The concentrations of C26:0, C24:0, C22:0 and C16:0 were determined by GC–MS in the indicated immune cell types. The relative amounts of (A) C26:0, (B) C24:0, (C) C22:0 normalized to C16:0 are shown. The statistical analysis of the accumulation of VLCFA is described in (D) as fold change of FA levels for AMN versus healthy control. Values represent means ± SEM. For all panels, the number of individuals (n) is indicated in the inset of (D). Note the different scaling (Student's t-test, ***P < 0.001; **P < 0.01).
Figure 3. Fatty acid levels in immune cells of healthy controls and AMN patients. The concentrations of C26:0, C24:0, C22:0 and C16:0 were determined by GC–MS in the indicated immune cell types. The relative amounts of (A) C26:0, (B) C24:0, (C) C22:0 normalized to C16:0 are shown. The statistical analysis of the accumulation of VLCFA is described in (D) as fold change of FA levels for AMN versus healthy control. Values represent means ± SEM. For all panels, the number of individuals (n) is indicated in the inset of (D). Note the different scaling (Student's t-test, ***P < 0.001; **P < 0.01).CC BY · PubMed Central
Figure 4. β-Oxidation in immune cells of healthy controls and AMN patients. The activity of (A) peroxisomal C26:0 and (B) mitochondrial C16:0 β-oxidation were measured in monocytes (CD14+), B cells (CD19+) and T cells (CD3+). The rate of β-oxidation is expressed as fmol 14C-labeled acetate released/min/106 cells. Values represent means ± SEM. The number of individuals (n) is indicated below the graphs (Student's t-test, ***P < 0.001; n.s., not significant).
Figure 4. β-Oxidation in immune cells of healthy controls and AMN patients. The activity of (A) peroxisomal C26:0 and (B) mitochondrial C16:0 β-oxidation were measured in monocytes (CD14+), B cells (CD19+) and T cells (CD3+). The rate of β-oxidation is expressed as fmol 14C-labeled acetate released/min/106 cells. Values represent means ± SEM. The number of individuals (n) is indicated below the graphs (Student's t-test, ***P < 0.001; n.s., not significant).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. 2008, FASEB J OFF PUBL FED AM SOC EXP BIOL, 22, 4201

Cited by

See all 63

Metadata

Authors
Weber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J.
Affiliations
Medical University of Vienna (AT)
Corresponding author
Berger, J.
Venue
Human Molecular Genetics
Published
2013-12-20
Volume
23
Issue
10
Pages
2542-2550
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2111369450
Cited by
63
References
47
Citations by year
2026: 2 · 2025: 3 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 7 · 2017: 4 · 2015: 9 · 2014: 5
FWCI
3.11
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Human Molecular Genetics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • European Commission (241622)
  • Austrian Science Fund (P26112-B19,)
  • Association Européenne contre les Leucodystrophies
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
X-linked adrenoleukodystrophy, ABCD1, ABCD2, ABCD3, very long chain fatty acids, peroxisomal ABC transporters, monocytes, lymphocytes, peroxisomal beta-oxidation, gene expression, demyelination, allogeneic hematopoietic stem cell transplantation
MeSH terms
ATP Binding Cassette Transporter, Subfamily D, ATP Binding Cassette Transporter, Subfamily D, Member 1, Adrenoleukodystrophy, Adult, Cells, Cultured, Fatty Acids, Humans, Lymphocytes, Male, Middle Aged, Monocytes, Oxidation-Reduction, Gene Expression, Case-Control Studies, ATP-Binding Cassette Transporters, Peroxisomes, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. https://app.cochat.ai/papers/10.1093/hmg/ddt645
The paper
Weber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J. (2014). X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddt645

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.